Avantor(AVTR)

Focus: Avantor is a large-scale life sciences company providing essential products and services to pharmaceutical, biotech, and healthcare customers globally. With $7B in annual revenue and 10,000+ employees, it operates as a critical infrastructure player rather than a traditional drug developer.

Profile data last refreshed 1h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Employees

10001+

Open Jobs

About Avantor

AI assessmentNot Hiring

No open roles listed right now. Follow Avantor to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$7.0B

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

SEC Filings: 2 available

Financials (FY2025)

Help build intelligence for Avantor

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Massive scale ($7B revenue) provides job security and access to enterprise-level pharma operations and supply chain networks — critical infrastructure role means consistent demand.
41 active R&D positions indicate significant expansion in research capabilities, suggesting career growth opportunity in a non-traditional pharma setting.
Publicly traded (NASDAQ: AVTR) with transparent financials and established corporate infrastructure — stability for long-term career planning.

Watch Out For

Revenue declined 6.7% YoY ($7.5B to $7.0B) and net income dropped 53% ($687M to $321M), signaling margin compression or headwinds in core business.
No pipeline, products, or clinical trials — this is a services/supplies company, not a drug developer, limiting exposure to drug development careers and therapeutic excitement.

Generated by Claude from Avantor's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Revenue

$7.0B7%

Net Income

$321M

Cash

$262M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo